181210-18-4

Basic information

• Product Name: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine
• Synonyms: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine
• CAS NO: 181210-18-4
• Molecular Formula: C₁₉H₂₄N₂O₂S
• Molecular Weight: 344.47106
• Mol File: 181210-18-4.mol

Chemical Properties

• Boiling Point: 472.597 °C at 760 mmHg
• Flash Point: 239.619 °C
• Appearance: /
• Density: 1.23
• CAS DataBase Reference: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(181210-18-4)
• EPA Substance Registry System: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(181210-18-4)

Safety Data

• Hazardous Substances Data: 181210-18-4(Hazardous Substances Data)

Usage

Uses

Given the provided materials, there are no specific applications listed for 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine. However, based on its chemical structure, it can be hypothesized that it may have uses in the following areas:
Used in Pharmaceutical Industry:
2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine could be used as a pharmaceutical compound for [specific application reason], given its unique structure and potential biological activity. The presence of the benzazepine backbone and various substituents may allow it to interact with specific biological targets or receptors, leading to potential therapeutic effects.
Used in Chemical Research:
In the field of chemical research, 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine may serve as a starting material or a model compound for studying the synthesis and properties of related compounds. Its complex structure could provide insights into the development of new synthetic routes or the exploration of novel chemical reactions.

Upstream product

• 50998-74-8 methyl N-tosylanthranilate 
• 24310-36-9 1-tosyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 134-20-3 2-carbomethoxyaniline 
• 98-59-9 p-toluenesulfonyl chloride 
• 881417-29-4 methyl-{4-(tetrahydro-pyran-2-yloxy)-1-[2-(toluene-4-sulfonylamino)-phenyl]-butyl}-carbamic acid tert-butyl ester 
• 881417-06-7 2-[1-tert-butoxycarbonylamino-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-07-8 2-[1-(N-methyl-tert-butoxycarbonylamino)-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-08-9 2-[1-(N-methyl-tert-butoxycarbonylamino)-4-(tetrahydropyran-2-yloxy)butyl]aniline 
• 881417-05-6 2-[1-azido-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-02-3 2-[1-hydroxy-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-00-1 2-(1-tert-butyldimethylsilyloxy-4-hydroxybutyl)nitrobenzene 
• 881416-99-5 2-(1-tert-butyldimethylsilylbut-3-enyl)nitrobenzene 
• 50-00-0 formaldehyd 
• 125715-24-4 1-(2-nitrophenyl)but-3-en-1-ol 

Downstream Products

• 165309-37-5 5-dimethylamino-1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-benzoazepine 
• 181210-00-4 N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-2-nitro-benzamide 
• 181210-02-6 2-Amino-N-[4-(5-dimethylamino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-benzamide 
• 137975-06-5 mozavaptan 
• 165309-36-4 5-dimethylamino-1-(4-nitro-benzoyl)-2,3,4,5-tetrahydro-1H-benzoazepine 
• 155061-62-4 5-dimethylamino-2,3,4,5-tetrahydro-1H-benzoazepine 

Relevant articles and documents

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

Efficient synthesis of functionalized benzazepine derivatives utilizing intramolecular mitsunobu reaction

The 5-hydroxy-2,3,4,5-tetrahydro-1H-benzazepine derivative (2), which is a typical metabolite of mozavaptan (1) having the 2,3,4,5-tetrahydro-1H-benzazepine skeleton, was synthesized by utilizing the intramolecular Mitsunobu reaction of the corresponding

Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds

This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V(1a)) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5- 1H-benzazepine series, compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity. A lipophilic group at the ortho position on the terminal benzoyl ring is important for both high V2 receptor affinity and oral activity. On the basis of these favorable properties, clinical testing of 31b has begun for use as an oral and iv aquaretic agent.